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Background/Aims: A drug-eluting stent for unresectable 
malignant biliary obstruction was developed to increase 
stent patency by preventing tumor ingrowth. The safety and 
efficacy of a new generation of metallic stents covered with a 
paclitaxel-incorporated membrane using a Pluronic® mixture 
(MSCPM-II) were compared prospectively with those of cov-
ered metal stents (CMSs) in patients with malignant biliary 
obstructions. Methods: This study was initially designed as a 
prospective randomized trial but was closed early because of 
a high incidence of early occlusion. Therefore, the data were 
analyzed using the intent-to-treat method. A total of 72 pa-
tients with unresectable distal malignant biliary obstructions 
were prospectively enrolled. Results: The two groups did not 
differ significantly in basic characteristics and mean follow-
up period (MSCPM-II 194 days vs CMS 277 days, p=0.063). 
Stent occlusion occurred in 14 patients (35%) who received 
MSCPM-II and in seven patients (21.9%) who received CMSs. 
Stent patency and survival time did not significantly differ 
between the two groups (p=0.355 and p=0.570). The com-
plications were mild and resolved by conservative manage-
ment in both groups. Conclusions: There were no significant 
differences in stent patency or patient survival in MSCPM-II 
and CMS patients with malignant biliary obstructions. (Gut 
Liver 2017;11:567-573)
Key Words: Drug-eluting stents; Biliary tract neoplasms; Pan-
creatic neoplasms; Self expandable metallic stents
INTRODUCTION
Biliary drainage through self-expandable metallic stent (SEMS) 
insertion is an important method of nonoperative management 
for unresectable malignant biliary obstructions.1-3 The SEMS 
has been proven to have superior patency and efficacy in com-
parison with plastic stents.4-6 Although the covered SEMS was 
developed to prevent the tumor ingrowth often seen with un-
covered SEMS, it is still controversial whether there are differ-
ences in stent patency between uncovered and covered SEMS.7 
In addition, both types of SEMS can become occluded over time 
due to tumor ingrowth or overgrowth, mucosal hyperplasia into 
the stent, chronic inflammatory reactions to the stent mesh, and 
biliary sludge or food impaction.8-10 
Since patency of SEMS is a significant factor in the prognosis 
of patients with malignant biliary obstruction,6 studies have 
investigated the use of stents that elute antitumoral agents to 
improve their patency through preventing occlusion by tumor 
growth.11-18 Previously, we demonstrated that endoscopic inser-
tion of a metallic stent covered with a paclitaxel-incorporated 
membrane (MSCPM-I) was safe and effective both in animals11 
and in a preliminary human study.12 However, a comparative 
prospective clinical study found no statistical differences in the 
duration of stent patency or survival time between MSCPM-I 
and non-drug-eluting covered metal stents (CMS).17 These re-
sults seem to be caused by biodegradation of the membrane and 
short-term release of paclitaxel from MSCPM-I. 
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To overcome these problems, we developed and modified a 
new-generation stent, a metallic stent covered with a paclitaxel-
incorporated membrane using a Pluronic® mixture (MSCPM-
II). Safety with enhanced local drug delivery of MSCPM-II 
was demonstrated in a previous animal study.18 The patency 
durations of MSCPM-II and conventional CMS in unresectable 
malignant biliary obstruction in humans were evaluated in this 
clinical study. The secondary goal was to compare the safety 




In this double-blind prospective randomized study, a total of 
150 patients (75 patients in each group) were found to be re-
quired, according to the following calculation using the param-
eters for a noninferiority trial: 2.5% type I error, 80% statistical 
power, permeable effective range 20% and drop-out rate 10%. 
However, this study was closed early due to the high drop-out 
rate. A total of 72 patients with unresectable distal malignant 
biliary obstruction were enrolled from three university hospitals 
from November 2011 to December 2013. Malignant biliary ob-
struction was diagnosed by clinical and radiologic findings and 
confirmed by pathologic results. 
The inclusion criteria were as follows: (1) adults between 19 
years and 90 years of age who voluntarily agreed to take part 
in this clinical trial and completed a signed consent form; (2) 
patients with unresectable pancreatic cancer or bile duct cancer; 
(3) patients who had not been previously treated with metallic 
stent insertion; (4) patients whose expected survival time was 
more than 3 months (Karnofsky scores ≥60); and (5) patients 
who were not pregnant. Subjects who corresponded to any of 
the following criteria were excluded from the trial: (1) patients 
who had previous surgical biliary drainage; (2) patients with 
severe bleeding diathesis; (3) patients with malignant hilar and/
or intrahepatic duct stricture; and (4) patients whose endoscopic 
intervention was judged to be impossible by the researcher. 
Chemotherapy was performed at each institution according 
to the patient’s disease, general condition, and tumor progres-
sion. The chemotherapy regimens used were gemcitabine-based 
chemotherapy (gemcitabine alone, gemcitabine plus erlotinib, 
gemcitabine plus capecitabine) and 5-fluorouracil (5-FU) plus 
oxaliplatin. Gemcitabine was administered intravenously at 
1,000 mg/m2 in 30-minute infusions three times weekly, every 
4 weeks. Erlotinib was administered orally at 100 or 150 mg/
day and capecitabine was administered orally at 1,660 mg/m2/
day (830 mg/m2 twice daily) for 3 weeks, followed by 1 week 
without chemotherapy.
The protocol was approved by the institutional review boards 
of the participating institutions (Gangnam Severance Hospital, 
Inha University College of Medicine, and Asan Medical Center) 
and all participants gave written informed consent (ClinicalTrials.
gov, NCT number: 01413386).
2. Stents
The MSCPM-II membrane (Niti-S stent, ComVi type with 
paclitaxel-eluting membrane; TaeWoong Medical, Kimpo, Ko-
rea) was composed of a double layer, in which the inner layer 
was made of polytetrafluoroethylene (PTFE) and the outer layer 
of paclitaxel-incorporated Pluronic® F-127–polyurethane (PTX–
Plu–PU). The coating solution was made from 400 mg PTX–
Plu–PU polymer and 10 mL tetrahydrofuran (THF). The PTX–
Plu–PU polymer was formed using polyurethane, 10% (wt/vol) 
paclitaxel (Taxol; SamYang, Daejeon, Korea), 10% Pluronic® 
F-127, and THF solution, which is used as a solvent for polyure-
thane. The safety of the MSCPM-II membrane was demonstrated 
in previous animal study.18 The membrane of the CMS (Niti-S 
stent, ComVi type; TaeWoong Medical) was covered with PTFE 
without paclitaxel. The MSCPM-II and CMS used in this study 
were 10 mm in diameter and 5 to 8 cm in length when fully ex-
panded.
Antibiotics for both gram-positive and gram-negative bac-
teria were prophylactically administered to patients to prevent 
infection and sepsis before the procedure. Biliary sphincter-
otomy was performed in all patients after biliary cannulation to 
facilitate stent insertion. Stents were inserted using endoscopic 
retrograde cholangiopancreatography (ERCP), in which stents 
were deployed along a guide wire under endoscopic and fluo-
roscopic guidance. Stents were inserted with an extra 1 to 1.5 
cm of coverage in the proximal and distal directions from both 
ends of the stricture.
3. Follow-up
Follow-up was performed for all enrolled patients in outpa-
tient departments, following an established protocol. Clinical 
symptoms and laboratory tests including liver function tests (to-
tal bilirubin, aspartate aminotransferase, alanine aminotransfer-
ase, alkaline phosphatase, and γ-glutamyl transpeptidase) were 
performed before, immediately after, and on the third and the 
seventh days post stent insertion, and every month thereafter. 
Computed tomography (CT) was performed before and 6 months 
after stent insertion. When stent occlusion was clinically sus-
pected during follow-up, CT and abdominal ultrasonography 
(US) were performed. 
4. Definition
Technical success was defined as successful deployment of a 
SEMS in the intended location with sufficient coverage of the 
stricture.19 Functional success was defined as a 50% decrease 
in or normalization of the bilirubin level within 14 days of 
stent placement. Recurrent biliary obstruction was defined as a 
composite endpoint of either occlusion or migration, and time 
to recurrent biliary obstruction refers to the time from SEMS 
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placement to the recurrence of biliary obstruction. Stent occlu-
sion was confirmed based on ERCP findings, and endobiliary 
biopsy and brush cytology were performed to differentiate the 
causes of occlusion.
Tumor ingrowth was defined as direct growth of tumors 
through the stent mesh, whereas tumor overgrowth was defined 
as growth of tumors at the proximal and/or distal ends of the 
stent. Stent migration referred to proximal or distal displace-
ment of the stent from the initial insertion site. Patients were 
regularly checked for procedure-related complications such as 
cholangitis, pancreatitis, cholecystitis, bleeding, and perforation; 
and the severity of complications was evaluated according to 
the consensus recommendations.19 The duration of stent patency 
and patient survival time were evaluated until obstruction of 
stent or until death of the patient.
5. Statistical analysis
Quantitative data were compared using the Student t-test, 
and results were expressed as means±standard deviations. The 
chi-square test and Fisher exact test were used to calculate dif-
ferences in categorical parameters. Stent patency and patient 
survival time in the two groups were compared using the cu-
mulative curve of the Kaplan-Meier lifetime table and Cox pro-
portional hazard ratio with a 95% confidence interval. All data 
were analyzed using SPSS version 12.0 (SPSS Inc., Chicago, IL, 
USA). The p-values less than 0.05 were considered statistically 
significant.
RESULTS
The insertions of MSCPM-II and CMS were performed en-
doscopically in 40 and 32 patients, respectively. Basic patient 
characteristics including mean age, male to female ratio, mean 
follow-up period, underlying disease status, and chemotherapy 
administration were not statistically different between the two 
groups (Table 1). Chemotherapy regimens used in this study 
were gemcitabine-based for pancreatic cancer and 5-FU-based 
for common bile duct cancer. 
Mean stent patency (MSCPM-II vs CMS; 130 days vs 139 
days; p=0.783) and mean survival time (MSCPM-II vs CMS; 
194 days vs 277 days; p=0.202) were not significantly different 
between the two groups (Fig. 1). Stent occlusion occurred in 14 
(35%) of the 40 MSCPM-II patients and seven (21.9%) of the 32 
CMS patients, and the rate of stent occlusion was not statisti-
cally different between the two groups (p=0.271) (Table 2). The 
main cause of stent occlusion was sludge impaction (MSCPM-
II, 11/14; CMS, 6/7). The other causes of stent occlusion were 
tumor ingrowth (MSCPM-II, n=1; CMS, n=1) and tumor over-
growth (MSCPM-II, n=2; CMS, n=0).
There was no procedure-related mortality, and the incidence 
of complications and stent migration did not differ significantly 
between the two groups. Cholangitis occurred in 12 patients in 
the MSCPM-II group and in eight patients in the CMS group on 
the day after stent insertion. Abdominal pain, fever, and wors-
ening jaundice were observed in these patients, but follow-up 
ERCP found no stent occlusion. Cholangitis was resolved within 
2 to 3 days with conservative management with antibiotics. 







Age, yr 69.9±12.4 67.8±14.9 0.647
Male:female 23:17 15:17 0.617
Follow-up period, day 194.2±152.1 277.0±198.4 0.063
Serum bilirubin level, mg/dL 
    Baseline 5.9±6.5 7.1±6.7 0.703
    1 Day after stent insertion 4.3±5.5 4.8±4.5 0.856
    4 Weeks after stent insertion 1.8±3.8 1.2±0.9 0.098
Diagnosis 0.751
    Pancreatic cancer  25 (62.5)  17 (53.1)
    CBD cancer  10 (25.0)  8 (25.0)
    Ampulla of Vater cancer  3 (7.5) 3 (9.4)
    GB cancer  2 (5.0)  4 (12.5)
Chemotherapy 0.881
    Gemcitabine-based  16 (40.0)  14 (43.7)
    Fluorouracil-based  3 (7.5)  1 (3.1)
Data are presented as mean±SD or number (%).
MSCPM-II, metallic stent covered with a paclitaxel-incorporated membrane; CMS, covered metal stent; CBD, common bile duct; GB, gallbladder.
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Two patients in the MSCPM-II group and two patients in the 
CMS group experienced mild pancreatitis, which improved with 
conservative management. Distal stent migration occurred in 
three patients in both the MSCPM-II and the CMS groups. The 
migrated stents were removed and replaced successfully with 
another conventional CMS. Multivariate analysis revealed that 
cancer type or chemotherapy regime did not influence stent pa-
tency or survival time between the MSCPM-II and CMS groups. 
DISCUSSION
Our previous single-arm pilot study demonstrated the safety 
and efficacy of MSCPM-I in 21 patients with malignant bili-
ary obstruction.12 However, a two-arm prospective compara-
tive study found no significant differences in stent patency 
or patient survival time between MSCPM-I and conventional 
CMS.17 These results were speculated to be affected by patient 
characteristics and stent membranes. The survival time of the 
patients enrolled in the study was short, and patient mortality 
before stent occlusion with MSCPM-I was approximately 50%. 
Therefore, since it was difficult to accurately measure stent pa-
tency over a long period, it is possible that stent patency was 
underestimated.17 In addition, the membrane used for MSCPM-
I was a single layer of polyurethane that could be biodegraded 
by hydrolysis, oxidation, and continuous contact with bile flow 
in vivo,13,20,21 which could lead to microcrack or hole formation 






Stent patency period, day 130.1±112.3 139.1±117.7 0.742
Survival period, day 194.2±152.1 277.0±198.4 0.079
Causes of stent occlusion 14 (35) 7 (21.9) 0.271
    Tumor ingrowth 1 (2.5) 1 (3.1) 0.875
    Tumor overgrowth 2 (5.1) 0 0.205
    Sludge impaction 11 (28.3) 6 (18.8) 0.385
Complication 19 (47.5) 14 (43.7) 0.892
    Cholangitis 12 (30.0) 8 (25.0) 0.642
    Cholecystitis 2 (5.0) 1 (3.1) 0.690
    Pancreatitis 2 (5.0) 2 (6.3) 0.823
    Stent migration 3 (7.5) 3 (9.3) 0.781
Data are presented as mean±SD or number (%).



















































































Fig. 1. (A) Kaplan-Meier graph showing the cumulative stent patency of a metallic stent covered with a paclitaxel-incorporated membrane using 
a Pluronic® mixture (MSCPM-II) and a covered metal stent (CMS). (B) Kaplan-Meier graph showing the cumulative patient survival of MSCPM-II 
and CMS.
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and induce stent occlusion by tumor ingrowth.13,22 Since stent 
occlusion might have occurred before the release of paclitaxel 
in MSCPM-I, the full evaluation of the inhibitory effects of 
MSCPM-I on tumor ingrowth was limited. To overcome the 
limitations of single-layer polyurethane, the double-layer drug-
eluting stent MSCPM-II was developed. The inner layer of 
MSCPM-II was composed of PTFE, which is resistant to degra-
dation by bile, and the outer layer was comprised of paclitaxel-
containing polyurethane.18 In addition, Pluronic® F-127 was 
added to MSCPM-II to achieve a constant release of paclitax-
el.18,23 While the stent patency of MSCPM-II was expected to be 
longer due to these modifications, there was no statistical differ-
ence in stent patency between the MSCPM-II group (130.1±112.3 
days) and the CMS group (139.1±117.7 days) (p=0.742).
Although this prospective study was performed using double-
blinded randomization, it was terminated early without enroll-
ing the target number of patients. The reason for this early ter-
mination was due to a high dropout rate in the first six months 
caused by early stent occlusion by food scraps. The ComVi stent 
(Niti-S stent, ComVi type; Taewoong Medical) was the base 
stent of both the MSCPM-II and CMS. Since the membrane of 
this stent was sandwiched between two wire layers, wires were 
exposed to both the inner and outer layer surfaces of the stent.24 
These naked wires were exposed to the inner lumen where food 
scraps could get caught and refluxed to the stent lumen and 
cause occlusions.24 In addition, the surface of the inner lumen 
was not smooth, which we also speculate played a major role in 
food impaction (Fig. 2). Moreover, protrusion of the uncovered 
portion into the duodenum may also cause occlusion.24,25 Food 
is caught more frequently by the wire mesh of the ComVi stent 
than by other metallic stents.
In other studies using non-drug-eluting ComVi stents, stent 
occlusion by sludge and food debris impaction occurred in 16% 
of cases,26 for which food scraps accounted for 15.9%.24 These 
rates are comparatively higher than those of other conventional 
CMS, at less than 4%.25 Stent occlusion by sludge and food 
debris impaction was as high as 28.3% in the MSCPM-II group 
and 18.8% in the CMS group in the present study, which is 
speculated to be caused by the ComVi stent characteristics. 
The time points of stent occlusion by sludge were 50.3±35.5 
days in the MSCPM-II group, and 64.1±47.2 days in the CMS 
group. Since the number of patients with early stent occlusion 
by sludge were high in both groups, this limited the evalua-
tion of the efficacy of tumor ingrowth prevention of MSCPM-
II. However, a subgroup analysis excluding patients who 
underwent early stent occlusion by sludge found no statisti-
cal differences in stent patency between the MSCPM-II group 
(160.5±116.8 days) and the CMS group (203.6±158.6 days). The 
A B
C D
Fig. 2. Structure and inner surface of 
a metallic stent covered with a pacli-
taxel-incorporated membrane using 
a Pluronic® mixture (MSCPM-II). (A) 
The MSCPM-II stent had the same 
structure as the ComVi stent. It had 
three layers (outer wire-membrane-
inner wire) and the inner surface 
was rough (due to the wire mesh). 
(B) After deployment, the uncovered 
portion of the stent protruded from 
the papilla to the duodenum. (C) 
A stent occluded due to food and 
sludge 1 month after stent insertion. 
(D) Although tumor ingrowth was 
not present, the inner surface of the 
stent was rough, resulting in a high 
risk of re-occlusion due to food and 
sludge.
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patency of the ComVi stents (208.1±173.3 days) in other studies 
showed a similar result to the present study.24 Thus, the pres-
ent study failed to prove efficacy of stent patency of MSCPM-II 
compared with conventional CMS. On the other hand, it is note-
worthy that stent occlusion by tumor ingrowth was as low as 
2.5% (1/40) and 3.1% (1/32) in the MSCPM-II and CMS groups, 
respectively. In a previous MSCPM-I study, stent occlusion by 
tumor ingrowth occurred in 22.4% (13/58) of the MSCMP-I 
group. Reduction of stent occlusion by tumor ingrowth in the 
MSCPM-II group compared with the MSCPM-I group might be 
due to suppression of membrane biodegradation by PTFE, which 
is more resistant to bile flow than is polyurethane. 
There was no significant difference in patient survival be-
tween the MSCPM-II and CMS groups regardless of the systemic 
chemotherapy regimen. In the previous MSCPM-I study, patient 
survival increased in pancreatic cancer patients treated with 
gemcitabine.17 In direct contrast, systemic gemcitabine had no 
effects on stent patency or patient survival in the present study. 
Nakai et al.27 reported that gemcitabine-based systemic chemo-
therapy had no effects on stent-related complications or stent 
patency. It is speculated that the discrepancies between previ-
ous results on MSCPM-I and the present results on MSCPM-II 
resulted from differences in enrolled patients. Although patients 
in the MSCPM-II group experienced cholangitis, cholecystitis, 
and mild pancreatitis, which were resolved by conservative 
management, there were no significant differences in incidence 
compared with the CMS group. Although this study failed to 
prove the efficacy of MSCPM-II through stent modification, its 
safety was proven in terms of inflammatory cell infiltration and 
fibrosis in an animal study,18 and no severe complications oc-
curred in this human trial. Therefore, we consider the safety of 
MSCPM-II in unresectable biliary malignancy to be clinically 
proven.
Although the two groups demonstrated no differences in 
stent patency, both the MSCPM-II and CMS groups had very 
low rates of tumor ingrowth in the present study. This could 
result from the effect of the bile acid-resistant PTFE membrane 
or the local antitumoral effects of the drug. However, since the 
administration of systemic chemotherapy, causative disease 
of malignant biliary obstruction, and time of the follow-up 
CT were heterogeneous in the present study, it was difficult to 
evaluate the changes of the cancer size. Because not all pa-
tients received systemic chemotherapy, it was hard to exclude 
its effects. In addition, since bile duct cancer, unlike pancreatic 
cancer which forms an original mass, has no measurable mass 
for comparative evaluation, there was a limitation in evaluating 
the changes of the mass size. Additionally, disease progression 
by metastasis caused more deaths than did disease progression 
by the primary lesion. Moreover, follow-up CT was performed 
6 months after the diagnosis, which was too late to measure the 
effect of MSCPM-II on primary sites due to disease progression, 
hampering accurate evaluation. In the future, a well-designed 
study on local drug therapy by drug-eluting stents is necessary.
In addition to the passive effects of suppressing tumor in-
growth, it would be expected that local therapy of the cancer 
adjacent to the stent would increase the patency of drug-
eluting stents. However, local therapy is possible only when the 
antitumor agent effectively penetrates the tumor mass. For a 
therapeutic agent to function on the target site in a biologically 
active state for a sufficient time, it is necessary to enhance the 
effects of the therapeutic agent within the tumor.28 Therefore, 
a new stent has been developed with the addition of sodium 
caprate to aid in antitumoral agent penetration of the tumor.29 
In addition, to prevent stent occlusion by food sludge, the new 
stent has been modified to increase inner lumen smoothness, in 
that the membrane is not sandwiched between two wire layers, 
but instead, the stent wire is sandwiched between two mem-
branes. A clinical trial is currently under way to assess this new-
ly modified stent (ClinicalTrials.gov, NCT number: 02460432). 
Limitations of the present study include early termination 
due to occlusion of the stent by food scraps, thus preventing the 
protocol of the study from being followed. Instead, the results 
were assessed using intention-to-treat analysis, limiting the 
extent to which we can prove the efficacy of nonvascular drug-
eluting stents. In addition, type II error may have occurred, 
since per-protocol analysis was not followed, and the number of 
enrolled patients was small. Another limitation is that the num-
ber of commercialized biliary stents with a PTFE-covered mem-
brane was too low for a comparison of efficacy with other cov-
ered SEMS. Nevertheless, drug-eluting stent insertion appears to 
be a promising, albeit challenging, procedure. It is necessary to 
challenge drug-eluting stent development through stent modifi-
cations and developments to overcome the problems associated 
with MSCPM-I and the limitations of MSCPM-II.
In conclusion, MSCPM-II showed no improved efficacy in 
terms of stent patency or survival duration in patients with ma-
lignant biliary obstructions compared with conventional CMS. 
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